Overview

Epinomics offered an epigenomics platform built around ATAC-seq, a method for mapping which parts of the genome are open and actively regulating genes. Its workflow combines the ATAC-seq lab steps with a data analytics engine to turn epigenetic data into insights about gene regulation, disease, and potential treatment responses. The platform works well with small numbers of cells, enabling high-resolution views of chromatin accessibility that support biomarker discovery and immuno-oncology research. After being acquired by 10x Genomics in 2018, its technology and team were integrated into 10x’s Chromium Single Cell ATAC solution to advance their product portfolio. The goal is to help researchers accelerate drug discovery and personalized medicine by decoding how epigenetic changes influence disease and therapy outcomes.